MedPath

BIKTARVY 50 MG/200 MG/25 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

BIKTARVY 50 MG/200 MG/25 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Pending
Register Number

181289001IP

Prescription Type

Uso Hospitalario

Authorization Date

May 17, 2022

Dosage Form

COMPRIMIDO RECUBIERTO CON PELÍCULA

Route: VÍA ORAL

Product Details

Detailed information about this CIMA AEMPS approved pharmaceutical product.

Basic Information

Key regulatory and product classification details

Regulatory Details

Register Number181289001IP
EMA Approved
Yes

Drug Classification

Generic
No
Orphan
No
Biosimilar
No
Commercialized
No
CIMA AEMPS Classification

INGREDIENTS (3)

BICTEGRAVIR SODIOActive
Quantity: 52,45 mg
Name: BICTEGRAVIR SODIO
EMTRICITABINAActive
Quantity: 200 mg
Name: EMTRICITABINA
TENOFOVIR ALAFENAMIDA FUMARATOActive
Quantity: 28,04 mg
Name: TENOFOVIR ALAFENAMIDA FUMARATO

ATC CLASSIFICATION (3)

J05A
J05AR
J05AR20

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.